Search results
Results from the WOW.Com Content Network
Talaromyces marneffei, formerly called Penicillium marneffei, [1] was identified in 1956. [2] The organism is endemic to southeast Asia, where it is an important cause of opportunistic infections in those with HIV/AIDS-related immunodeficiency. Incidence of T. marneffei infections has increased due to a rise in HIV infection rates in the region ...
Penicillium marneffei, [1] penicilliosis [2] or penicillosis [3] Specialty: Infectious diseases: Symptoms: skin lesions, fever, anaemia, large lymph glands, large liver. [2] Sometimes none. [4] Causes: Talaromyces marneffei [1] Risk factors: HIV/AIDS, long-term steroids, organ transplant, old age, malnutrition [4] Diagnostic method
A new strain of Penicillium was isolated from hepatic lesions on a bamboo rat used for experimental infections at the Institute in 1956. Penicillium marneffei was named for Hubert Marneffei, Director of the Pasteur Institute of Vietnam. [5] The institute was still publishing articles in French as late as 1959. [6]
For example, the incidence of tuberculosis in patients with advanced illness is high in Taiwan (24.6%) and the rate of endemic fungal (Penicillium marneffei) infections is increasing. [ 17 ] [ 18 ] On the positive side, the effort by the Taiwanese Government since April 1997, to distribute highly-active antiretroviral therapy for free [ 19 ...
An HIV vaccine is a potential vaccine that could be either a preventive vaccine or a therapeutic vaccine, which means it would either protect individuals from being infected with HIV or treat HIV-infected individuals. It is thought that an HIV vaccine could either induce an immune response against HIV (active vaccination approach) or consist of ...
In an interview with Yahoo News, Dr. Anthony Fauci discussed the state of HIV vaccine research after the recent failure of a late-stage trial funded by the National Institute of Allergy and ...
AIDSVAX is an experimental HIV vaccine that was developed originally at Genentech in San Francisco, California, and later tested by the VaxGen company, a Genentech offshoot. [1] The development and trials of the vaccine received significant coverage in the international media, but American trials proved inconclusive.
The critical problem that has bedeviled HIV vaccine research for decades, Fauci noted, is a crucial weakness that the virus already successfully exploits: The natural immune response to infection ...